These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30883242)

  • 1. Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.
    Del Alcázar E; Ferran M; López-Ferrer A; Notario J; Vidal D; Riera J; Aparicio G; Gallardo F; Vilarrasa E; Alsina M; Puig L; Ferrándiz C; Carrascosa JM
    J Dermatolog Treat; 2020 May; 31(3):222-226. PubMed ID: 30883242
    [No Abstract]   [Full Text] [Related]  

  • 2. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
    Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
    J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.
    Hayashi M; Umezawa Y; Fukuchi O; Ito T; Saeki H; Nakagawa H
    J Dermatol; 2014 Nov; 41(11):974-80. PubMed ID: 25346301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
    Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
    Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis.
    Feldman SR; Narbutt J; Girolomoni G; Brzezicki J; Reznichenko N; Zegadło-Mylik MA; Pulka G; Dmowska-Stecewicz M; Kłujszo E; Rekalov D; Rajzer L; Lee J; Lee M; Rho YH
    J Am Acad Dermatol; 2024 Sep; 91(3):440-447. PubMed ID: 38685404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg.
    Llamas-Velasco M; Baniandrés O; Rivera R; Reymundo Jimenez A; Hospital M; García Zamora E; González-Cantero Á; Andrés Lencina JJ; Daudén E; de la Cueva P
    Dermatol Ther; 2020 Jul; 33(4):e13678. PubMed ID: 32447810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
    Reich K; Pinter A; Lacour JP; Ferrandiz C; Micali G; French LE; Lomaga M; Dutronc Y; Henneges C; Wilhelm S; Hartz S; Paul C;
    Br J Dermatol; 2017 Oct; 177(4):1014-1023. PubMed ID: 28542874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
    Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.
    Laws PM; Downs AM; Parslew R; Dever B; Smith CH; Barker JN; Moriarty B; Murphy R; Kirby B; Burden AD; McBride S; Anstey AV; O'Shea S; Ralph N; Buckley C; Griffiths CE; Warren RB
    Br J Dermatol; 2012 Jan; 166(1):189-95. PubMed ID: 21929536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal Hyperproliferation With Less Prominent Dermal Inflammation Is the Unique Histopathological Feature of the Refractory Lesions in Psoriasis Treated With Ustekinumab.
    Kim M; Yang S; Kim BR; Youn SW
    Am J Dermatopathol; 2022 Apr; 44(4):267-271. PubMed ID: 34726183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
    Talamonti M; Galluzzo M; van den Reek JM; de Jong EM; Lambert JLW; Malagoli P; Bianchi L; Costanzo A
    Br J Dermatol; 2017 Aug; 177(2):489-496. PubMed ID: 28207934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
    Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
    Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
    Stull DE; Griffiths CEM; Gilloteau I; Zhao Y; Guana A; Finlay AY; Sherif B; Houghton K; Puig L
    Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks.
    Toro-Montecinos M; Ballescá F; Ferrandiz C; Teniente-Serra A; Martinez-Caceres E; Carrascosa JM
    J Dermatolog Treat; 2019 Feb; 30(1):35-39. PubMed ID: 29683393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
    N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Paul C; Kragballe K; Luger T; Lambert J; Chimenti S; Girolomoni G; Nicolas JF; Rizova E; Brunori M; Mistry S; Bergmans P; Barker J;
    Br J Dermatol; 2014 Feb; 170(2):435-44. PubMed ID: 24116868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.